LENSARLNSR
LNSR
About: LENSAR Inc is a commercial-stage medical device company focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, simplified procedure planning, efficient design, and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. Geographically, the company generates the majority of its revenue from the United States, followed by Europe and Asia.
Employees: 140
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
417% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 6
277% more call options, than puts
Call options by funds: $1.11M | Put options by funds: $293K
73% more capital invested
Capital invested by funds: $32.6M [Q4 2024] → $56.5M (+$23.9M) [Q1 2025]
50% more funds holding
Funds holding: 44 [Q4 2024] → 66 (+22) [Q1 2025]
18% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 11
2.54% more ownership
Funds ownership: 31.37% [Q4 2024] → 33.91% (+2.54%) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$15
20%
upside
Avg. target
$15
20%
upside
High target
$15
20%
upside
1 analyst rating
0 positive
0%
1 neutral
100%
0 negative
0%
Lake Street Frank Takkinen | 20%upside $15 | Hold Downgraded | 24 Mar 2025 |
Financial journalist opinion
Neutral
Business Wire
1 week ago
LENSAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LENSAR, Inc. - LNSR
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of LENSAR, Inc. (NasdaqCM: LNSR) to Alcon Inc. (NYSE: ALC). Under the terms of the proposed transaction, shareholders of LENSAR will receive $14.00 in cash, with an additional non-tradeable contingent value right offering up to $2.75 per share in cash conditioned on achievement of a milestone, for each.
Neutral
GlobeNewsWire
1 week ago
LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ORLANDO, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR's board of directors granted 10 newly-hired non-executive employees an aggregate of 3,090 restricted stock units (“RSUs”). The RSUs were granted as of June 2, 2025, as inducement for each such employee commencing employment with the Company. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
1 month ago
LENSAR Reports First Quarter 2025 Results and Provides Business Update
14 ALLY Robotic Laser Cataract Systems™ (“ALLY Systems”) placed in 1Q 2025 with an additional backlog of 24 systems pending installation as of March 31, 2025
Neutral
Business Wire
2 months ago
LENSAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LENSAR, Inc. - LNSR
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of LENSAR, Inc. (NasdaqCM: LNSR) to Alcon Inc. (NYSE: ALC). Under the terms of the proposed transaction, shareholders of LENSAR will receive $14.00 in cash, with an additional non-tradeable contingent value right offering up to $2.75 per share in cash conditioned on achievement of a milestone, for each.
Positive
Zacks Investment Research
2 months ago
ALC Stock Rises Following the Merger Agreement With LENSAR
Alcon enters into a definitive merger agreement to acquire LENSAR's ALLY Robotic Cataract Laser Treatment System, proprietary Streamline software technology and LENSAR legacy laser system.
Neutral
PRNewsWire
2 months ago
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of LENSAR, Inc. - LNSR
NEW YORK , March 24, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating LENSAR, Inc. (NASDAQ: LNSR ), relating to the proposed merger with Alcon.
Neutral
Business Wire
2 months ago
Shareholder Alert: The Ademi Firm Investigates Whether LENSAR, Inc. is Obtaining a Fair Price for Its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating LENSAR (NASDAQ: LNSR) for possible breaches of fiduciary duty and other violations of law in its transaction with Alcon. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, LENSAR shareholders will receive only $14.00 per share in cash (an aggregate implied value of approximately $3.
Neutral
Business Wire
2 months ago
LNSR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of LENSAR, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of LENSAR, Inc. (NASDAQ: LNSR) to Alcon for $14.00 per share in cash, with an additional non-tradeable contingent value right offering up to $2.75 per share in cash conditioned on achievement of a milestone, is fair to LENSAR shareholders. Halper Sadeh encourages LENSAR shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper.
Neutral
GlobeNewsWire
3 months ago
LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ORLANDO, Fla., March 03, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR's board of directors granted two newly-hired non-executive employees stock options to purchase an aggregate of 1,600 shares of the Company's common stock. The options were granted as of March 3, 2025, as inducements material to each employee entering into employment with the Company. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
Seeking Alpha
3 months ago
LENSAR, Inc. (LNSR) Q4 2024 Earnings Call Transcript
LENSAR, Inc. (NASDAQ:LNSR ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Cameron Radinovic - Investor Relations, Burns McClellan Nicholas Curtis - Chief Executive Officer Thomas Staab - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Operator Good morning and thank you for your participation. At this time, all participants are in listen-only mode.
Charts implemented using Lightweight Charts™